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Purpose: The uptakes of radiolabel led AnnexinA5 (AnxA5) and a size-matched control protein in
experimental tumours were evaluated by kinetic analyses and compared with standard uptake values
(SUVs) to investigate whether the method of analysis may impact on the conclusions that can be drawn.
Procedures: PET scans of the 11C-labelled proteins performed in untreated and doxorubicin-treated mice with
head and neck carcinoma xenografts were retrospectively analysed. The appropriateness of using the Logan
graphical analyses for reversibly binding radiotracers in these models was evaluated and conﬁrmed.
Distribution volume ratios (DVRs) of the regions of interest to referencemuscle tissuewere compared to those
based on the image-derived input function from arterial blood. SUVs were calculated in the same individuals.
Results: DVRs based on reference muscle tissue gave results similar to those based on the arterial blood and
may be preferred since they are simpler to calculate. In the inter-group comparisons of baseline versus
chemotherapy treatment or AnxA5 versus control protein, differences in DVR quantiﬁcations had a 20- to 40-
fold higher statistical signiﬁcance than differences in SUVs. As quantiﬁed using the control protein, the
amount of free ligand in the vascular space of tumours may be large due to enhanced permeability and
retention (EPR) contributions at baseline and affected during treatment, which has implications for
quantiﬁcations of the speciﬁcally bound radioligand.
Conclusions: These results demonstrate that the quantiﬁcation method as well as the controls used can be
important for interpreting the uptake in tumours of the medium-sized protein ligand AnxA5 and its use in
monitoring the effects of therapy on cell death in the tumours.
Advances in knowledge and implications for patient care: These results provide additional support for the
recognition that more detailed investigations on the effects of the tumour microenvironment on the targeting
capability of imaging radiopharmaceuticals are needed.
© 2014 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Non-invasive molecular imaging methods in positron and single
photon emission tomography (PET and SPECT, respectively) are
usually tested pre-clinically prior to implementation in human
subjects. Since the development of dedicated cameras with optimised
spatial resolution [1], imaging strategies are more and more
frequently optimized in rodents [2,3]. Methods for analysing the
results obtained in rodents generally follow those that have been used
for many years in humans, and radiotracer behaviour is most often
characterized as normalized uptakes in tissues. Kinetic modeling can
be used to quantitate physiological parameters that aremore sensitive
for showing individual variations, but the techniques that have been
developed for use in humans need to be adapted to and validated for
the animals/strains and the applications studied [4,5].(S. Stone-Elander).
-NC-ND license.In this study we examine the use of a method for quantifying the
behaviour in tumour-bearing mice of a medium-sized (36 kDa)
protein AnnexinA5 (AnxA5) labelled with positron-emitting carbon-
11 through a C-terminal selenocysteine tag (ST) [6]. The biological
basis for the molecular imaging strategy is that cells externalize
phosphatidylserine (PS) when they die, especially through apoptosis
and necrosis, and that the endogenous human protein AnxA5 binds
selectively and with high afﬁnity (1 nM) to PS [7]. Therefore, non-
invasive observation of the binding of radiolabeled AnxA5 to tissues
with externalized PS should enable the localization and estimation of
cell death under different conditions. The uptake of radiolabeled
AnxA5-based probes has been used preclinically as well as clinically as
a marker for spontaneous and induced cell death in e.g. ischemia and
in tumours [8]. However, considerable work has been required to
optimize strategies for site-speciﬁcally labeling the proteinwith 99mTc
for SPECT imaging, andmore recently, with the PET nuclides 18F, 68Ga,
124I and 11C (see e.g. [9] and references therein). Differences in levels
of baseline cell death versus therapy-induced changes at discrete
times have often been difﬁcult to detect or accurately quantify. These
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the processes being studied and have limited a wide utilization of this
AnxA5-based imaging. Recently a human PS-targeting antibody 89Zr-
labeled PGN635 was introduced as a new strategy for imaging
dynamic apoptotic processes since the antibody probes have plasma
half-lives on the order of weeks and therefore might be able to image
cumulative apoptosis occuring over time [10]. Alternatively probes for
visualizing other biomarkers of cell death in vivo are also being
evaluated [9]. Since the optimal imaging strategy has not yet been
agreed upon, further investigations on the underlying factors affecting
the quantiﬁcation of these imaging probes are motivated.
Most previous AnxA5-based studies have been primarily evaluated
in the region of interest (ROI) using static imaging at relatively late
times and the standard assessment methods (see e.g. [11]) widely
used in clinical imaging. For rapidly localizing probes, it can also be
feasible and sometimes desirable to dynamically measure concentra-
tions of radioactivity in an ROI and in reference tissues and observe
changes as time activity curves (TACs) over time after radiotracer
administration. Both methods can be sufﬁcient to describe the
behaviour of the tracer if, for example, the uptake in an ROI is
signiﬁcantly different from that in a baseline study or in a reference
tissue and the in vivo behaviour of the radiotracer and its metabolism
have been characterized and accounted for. That may, however, be
more difﬁcult to do in peripheral tissues since radiometabolites are
not necessarily stopped by tissue barriers (like in the brain) and may
therefore contribute to thenon-speciﬁcuptake. Furthermore, in tumours
an enhanced permeability and retention (EPR) caused by leaky blood
vessels and compromised lymphatic drainage [12] can increase the
amount of tracer accumulating due to non-binding mechanisms.
Compartmental analyses of dynamically acquired data are consid-
ered to be more accurate and, in some cases, necessary for
appropriately describing radiotracer behaviour [13–15], though they
are often not considered practical in high throughput clinical imaging.
These methods have historically been developed for quantifying
receptor ligands in the brain (e.g. [16,17]). Applications in peripheral
tumours have been reported (e.g. [18,19]), though very seldom for
macromolecular probes (e.g. [20]) and, to our knowledge, not
previously with AnxA5-based imaging probes.
In compartmental analyses, the free, non-speciﬁcally and specif-
ically bound tracers are separated into well-delineated compartments
(see e.g. [21]). However, near-equilibrium between non-speciﬁcally
bound and the free tracer is rapidly achieved. This justiﬁes omitting
one compartment, leaving two-compartment models which are more
easily analysed. Combinations of in- and outﬂow parameters which
deﬁne the speciﬁc compartment enable the determination of macro
parameters such as the binding potential and the distribution volume
[22,23]. Contributions from free tracer must be estimated, usually
from the metabolite-corrected radioactivity in arterial blood. Contin-
uous collection of blood samples is, however, invasive and is not
possible when the available blood volume is a limiting factor as in
studies in small animals. Therefore, alternative graphical methods
have been developed that instead of arterial blood use a reference
tissue devoid of speciﬁcally bound tracer to assess the contribution
from the free tracer [24,25]. The reliability of these graphical methods
must be demonstrated for each tracer and each reference tissue.
When used in studies in peripheral tissues this veriﬁcation procedure
can be even more complex due to the wider size range of the tracers
(small molecules to peptides, proteins or antibodies and their
fragments) that can be utilized in peripheral organs and the
complexity in the factors affecting their retention in different tissues.
Here a graphical analysismethod is used to describe the behaviour of
the 11C-labeled AnxA5 in experimental tumours and reference muscle
tissue. In order to assess non-speciﬁc contributions related to the
vascularity of the tumours,weuseda control proteinof similar size to the
AnxA5 but with no apparent binding behaviour: mutated thioredoxin
fused with green ﬂuorescent protein (mTrx-GFP) which was alsosimilarly labelled with carbon-11 [6]. The macro parameter results for
these two proteins are compared to those obtained by conventional
uptake assessments in non-treated and chemotherapy-treated tumour-
bearing mice.
2. Materials and methods
Experiments were performed in accordance with national
legislation on laboratory animals' protection and were approved
by the local ethics committee for animal research. The animals used
in this trial were permitted food ad libitum until the morning of
the PET procedures.
2.1. Radioligands
The preparations of the ligands used here, H6-AnxA5-ST and its
size-matched control protein, H6-mTrx-GFP-ST, have been present-
ed elsewhere [26]. In brief, these proteins were expressed with a
his-tag on the N-terminus to facilitate protein puriﬁcation and on
the C-terminus with a selenocysteine tag to enable site-speciﬁc
labelling with positron-emitting carbon-11 (11C) labeled methyl
iodide (t1/2 ≈ 20 min) under relatively mild conditions. Due to the
short half-life of the radionuclide, PET studies are restricted to
approximately one hour scan time. If the tracers bind reversibly, they
should reach semi-equilibrium during that hour. AnxA5 does bind
reversibly to the phosphatidylserine externalized after induction of
cell death [27]. Uptake of the [methyl-11C]-H6-AnxA5-ST-CH3 in head
and neck carcinoma xenografts has been observed to reach a
maximum at around 30 min, plateau and tend to decrease slightly
at the end of a 60 min scan [6]. These characteristics indicated that
the compartmental methods for reversible [28,29] rather than
irreversible tracers [30] could be more appropriate, which is further
evaluated here (see results 3.2).
2.2. In vivo microPET studies
The PET camera used was the microPET Focus 120 (Concorde,
Siemens), which has been previously extensively evaluated [31]. The
ﬁeld of view is 7.6 and 10 cm for axial and trans-axial dimensions,
respectively. Data were continuously collected in list mode, corrected
for dead time, randoms and physical decay and histogrammed as
follows: 3 seconds × 20 frames, 150 seconds × 8 frames and
293 seconds × 8 frames. Subsequent recontruction was conducted
using ordered subset expectation maximisation in 2 dimensions
(OSEM2D) employing 4 iterations and 16 subsets. The software used
to analyse the PET data and perform the compartmental analyses was
the Inveon Research Workplace (IRW) developed by Siemens. When
additional data analyses were required, the Matrix Laboratory
(MatLab) software was used. Whole body ROIs were analysed to
examine whether all radioactivity is accounted for in the measure-
ments (i.e. assess whether there are losses due to excretion and
exhalation). The uptake of radioactivity in blood, reference tissue and
tumour regions was examined to see if secular or transient
equilibrium conditions were satisﬁed during the one hour period
after the bolus tracer administration.
2.3. Tumour model
Severe combined immunodeﬁciency (SCID) mice were inoculated
with head and neck carcinoma (FaDu) cells on the right shoulder, well
separated from other tissues with appreciable uptake of the
radiotracers in order to minimize spillover effects. Xenografts were
allowed to grow for about ten days until the smallest diameter (by
palpation) was at least three times the full width half maximum
(FWHM) of the camera (range 4–9 mm) to minimize partial volume
effects. As controls, ﬁve untreated tumour-bearing animals were
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(Anxbase) and ﬁve with [methyl-11C]-H6-mTrx-GFP-ST-CH3 (GFPbase).
Additionally, ﬁve tumour-bearing mice were treated with the
chemotherapeutic agent doxorubicin and, 72 h after a single
administration, were scanned with [methyl-11C]-H6-AnxA5-ST-CH3
(Anxtreated). The radioactivity injected, 0.192–0.373 MBq per gram
body weight, was determined by measuring the syringe before
and after the injection as well as lines and other possible
residual radioactivities. Effective speciﬁc radioactivity was about
5000–10000 MBq/μmol, based on the total unlabeled protein used in
the labeling experiments. About 1 nmole of protein was injected
per animal.
Statistical gains would have been expected if these studies had
been performed longitudinally and each treated animal was its own
control. However, in this case it was a priority to be able to correlate
the estimations of cell death induction revealed in these tumours with
PET with ex vivo tissue and serum analyses, which have been
previously reported [6]. In the present study the methods for
quantifying the PET data for these inter-individual comparisons are
analysed in more depth.
2.4. Conventional uptake measurements
Conventional uptake is measured and evaluated by the widely
used standard uptake value (SUV). The SUV is deﬁned as
SUV¼ radiotracer concentration
injected activity=NormalisationFactor
ð1Þ
in which the normalisation used here was to body weight. SUV was
computed for every reconstructed time frame. When the last
25 minutes were used to include more data, the mean uptake
was affected slightly, ≈2%, by the tendency of [methyl-11C]-H6-
AnxA5-ST-CH3 uptake to decrease after 35 min [6]. Therefore only
SUVs calculated at semi-equilibrium, 30 to 35 minutes after the PET
scanning was initiated, were used in the comparisons.
2.5. Kinetic modelling
The distribution volume (DV) and binding potential (BP) [23] are
the macro parameters most often estimated when describing the
tissue uptake of a radioligand. The BP relates the speciﬁc binding of
the radioligand to a target to some other reference concentration. The
DV relates the concentration of a radioligand in a tissue to the total
concentration in plasma. Target tissues may contain radioligand that
is speciﬁcally bound, non-speciﬁcally bound or free in tissue water.
The non-displaceable BP (BPND) and the distribution volume ratio
(DVR) relate the corresponding radioligand quantiﬁcations in a
receptor-rich ROI to those in a receptor-free reference tissue. We
previously [6] have described the tissue uptake of the radioligands
studied here using BPND. However subsequent analyses have
indicated that DVR might be a more appropriate parameter since
the non-speciﬁc uptake in the tumour tissue may be quite large, may
vary from one subject to another and also due to treatment effects.
Here we use the commercially-supplied (IRW) software to
calculate and validate the DVR obtained by the Logan graphical
method [25]. This method hereafter, referred to as Loganref, was
originally developed for describing the binding of radioligands to
central neuroreceptors. Loganref is a data-driven method. In other
words it does not a priori assume a speciﬁc number of compartments.
Macro parameters of interest are determined by the gradient of the ﬁt
of certain measured points. The ﬁt is adjusted so that as many points
as possible are included while simultaneously minimising the
associated chi-squared value. The number of points that were used
in each ﬁt may therefore vary. Here we required at least seven points.The apppropriateness of the tissue chosen as a reference tissue
must be veriﬁed. This is done by observing some intrinsic compart-
mental parameter ratio when changing compartmental set-up, e.g.
Kone compartment1
.
Ktwo compartment1
ð2Þ
which was used here. We assumed that if there are no extra in-/
outﬂows, i.e. no additional compartments, this ratio will not be
signiﬁcantly different from unity when comparing a one-compart-
ment to a two-compartment model. This assumption was further
conﬁrmed by performing an F-test (MatLab).
To validate the use of a reference tissue method in the peripheral
tissues, the DVR was estimated by the Logan method using an arterial
blood input [28], hereafter referred to as Loganart. Both Loganref and
Loganart assume that the reference region, the arterial blood and the
impulse response function reacha linear relationship for t N t´ (here t´was
35 minutes). The method with arterial input yields the DV. By
subsequently dividing the DV of the target ROI by the DV of the reference
tissue, theDVR is obtained. Thecalculationof theDVRby the IRWsoftware
was initially veriﬁed by also performing the calculations with MatLab.
Three different image-based ROIs were used: the tumour, the
reference region and the arterial blood. The radioactivity concentration
in the arterial blood throughout the dynamic PET scan was obtained
from a left heart chamber ROI, which was delineated in a 3 second
interval during the ﬁrst ten seconds. The volume of this ROI was
approximately 20 mm3. Spatial resolution was improved and partial
volume effects somewhat controlled by using iterative reconstructions
[32]. Iterations in OSEM were perfomed until no signiﬁcant improve-
ment could be observed in the resulting image. The minimum tumour
and reference tissue dimensions included in the study were 3–7 times
the resolution. Further partial volume corrections could have been
achieved by ﬁltering [33]. However valuable information may be lost
during ﬁltering, and this could potentially have a large impact on the
statistics of small ROIs in mouse imaging. Bias due to movement could
not be corrected by gating, since appropriate sensors for mice are not
readily available. However, the tumour and the reference region were
located on the shoulder and thigh, respectively, where motions due to
breathing and heart beating were expected to have a low impact. The
heart ROI was drawn using pixels as centrally located in the left heart
chamber as possible. The tumour ROI was drawn when considerable
uptakeof radioactivitywas observed, in this case in the time framesafter
35 min. First, a so-called primary ROI, based on the dimensions of
excised tissues determined ex vivo, was drawn manually for each
separate tumour and ﬁtted to the tumour dimensions in the sagittal,
coronal and trans-axial planes of the images. Secondary ROIs were then
created by applying intensity thresholds to the tumour inside the
primary ROI in order to minimize subjective interpretations and
increase reproducibility [34]. This secondary ROI was used in the
subsequent analyses. Appropriate shapes of the ROI TACs were
conﬁrmed by visual inspection (one and the same observer). Noticeable
shifts in body positioning during the study led to exclusion from the
analyses. The ROI for the reference tissue was drawn over both
hamstring muscles, and the reference tissue most consistent with the
requirements given above (Eq. (2) ≈ 1)was chosen. The size of this ROI
was similar to that of the tumour. Intensity thresholding was also
applied to the reference ROI. Regions with more intense uptake and
assumed to be joints were omitted using two-sided thresholding.
In Loganref the outﬂow rate parameter of the reference tissue, k2ref,
approximates the plasma integral. Amean value is often used, or it can
be neglected. Here the k2ref was ﬁrst calculated using the simpliﬁed
reference tissue model [35]. However, this is a model-driven method
(i.e. assumes a particular number of compartments), which we
wanted to avoid during this validation. Neglecting k2ref altered the
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affected. Therefore we concluded that neglecting k2ref was justiﬁed.
2.6. Statistical analysis & signiﬁcance assessment
A QQ-plot (Matlab) analysis of the macro parameter was
performed, and the results were not consistent with a normal
distribution. Therefore the t-test was not employed. Instead, a
Wilcoxon two sample rank sum test was used to test the null
hypothesis that there was no difference between the groups for the
calculated SUVs and DVRs for the doxorubicin treated animals versus
the untreated animals for the 11C-labeled H6-AnxA5-ST and H6-mTrx-
GFP-ST.
Cohen's d calculated as M2−M1pooled std deviation was used to indicate the
difference between the means of groups. The size of Cohen's d is a
measure of the strength of the relationship between two variables and
is primarily used as a complement to e.g. the t-test or VINOVA.When d
equals 2 there is a difference of approximately two standard
deviations whereas a d of 0.5 equals a difference of approximately
half a standard deviation.
3. Results
3.1. Conﬁrmation of radioactivity accountability by examinations of
whole body ROIs
Whole body time activity curves for [methyl-11C]-H6-AnxA5-ST-
CH3 and the size-matched [methyl-11C]-H6-mTrx-GFP-ST-CH3 were
compared. The similarities in themean results for all the controls used
here are illustrated in Fig. 1. For both tracers the total body
radioactivity decreases from 100% of the injected amount to
approximately the same level, ≈80–85%, at the end of the 60 min
scan. These losses appear to be losses from the selenocysteine-11C
label since in several other N-11C-labeled small molecules similarly
analysed N 98% of the injected radioactivity was accounted for over
the 60 min scan (data not shown). This decrease is interpreted to be
due to exhalation of volatile metabolites. The total amount of
radioactivity in the body is essentially the same for the two tracers
throughout the scan. On a regional level, the only tissue uptake
differences previously observedwere a highermaximum radioactivityFig. 1.Whole body ROI comparisons accounting for the entire radioactivity in the body
after administration of the two tracers used in this study. The uptake was here
normalised to the maximum uptake and multiplied by 100. The error bars represent
standard deviation of the mean.level in the kidneys and higher molecular weight 11C-labeled protein
excreted to the urine after the AnxA5 administrations [6]. Radioac-
tivity in the blood and plasma was also previously shown to be
primarily (≈95%) in high molecular weight forms up to 40 min
[26], and therefore metabolite contributions were not further
considered here.
3.2. Test of equilibrium at t N t’ and validation of the use of muscle tissue
as a reference tissue
An image demonstrating the uptake of [methyl-11C]-H6-
AnxA5-ST-CH3 and the tumour ROI delineation is given in
Fig. 2A. In order to determine if and at which time the uptake of
[methyl-11C]-H6-AnxA5-ST-CH3 satisﬁed secular or transient equi-
librium conditions after the bolus tracer administration [36] and
the appropriateness of using muscle tissue as a reference tissue,
the time proﬁles for concentrations of radioactivity (measured in
SUVs) in different regions were examined in one typical animal.
After the initial distribution phase, the concentrations in the
arterial blood tended to level off from approximately 35 min to
the end of the scan (Fig. 2B), with a slope during this period
calculated to be approximately −0.0455. The ratio of Cmuscle/
Cartblood, reﬂecting the variation of non-speciﬁc and free radi-
oligand in the chosen reference tissue over time, increased slowly
but tended to level off with a slope of 0.0007 during the last
20 min (Fig. 2C). The ratio of Ctumour/Cmuscle increased between 5
and 20 min, levelled off before decreasing slightly to a plateau
with a slope of −0.0079 between 40 and 60 min (Fig. 2D). Thus
the concentrations in the region containing the speciﬁc binding
and that of the reference tissue reach an approximate secular
equilibrium during the last 20 minutes of the 60 min scans.
Furthermore the reference tissue TAC was subtracted from the
tumour TAC to show “speciﬁc” uptake of the radioactivity
(e.g. [37]). The TACtumour-TACref plateaued from around 30–
35 min generally until the end of the experiment with, in several
animals, a slight tendency to decrease. As a further control, all
baseline tumours were also analysed using the Patlak graphical
method for irreversibly binding tracers [24]. The residuals
between the ﬁtted line and the measured data points did not
result in horizontal lines (i.e. the plots were non-linear), which
indicated that the data are not adequately described by this
method for irreversible tracers. All these results together support
the use of the Logan method for reversible tracer kinetics.
An example of the Logan plots obtained for baseline investigations
with the 11C-labeled AnxA5 is shown in Fig. 3A. The DVRs for the 11C-
labeled AnxA5 and mTrx-GFP probes in the FaDu xenografts were
calculated using the Logan graphical method with either the arterial
blood or the reference muscle tissue. The reference tissue was
validated and approved using both Eq. (2) and the F-test. The Loganart
gave slightly different DVRs than the Loganref on an individual level, as
shown in Fig. 3B. However, the differences are not signiﬁcant on the
group level. Therefore, we conclude that the Loganref method, which
is simpler to perform, is also acceptable in extracerebral analyses of
these two tracers in this model.
3.3. Comparison of tracer uptake estimations by conventional uptake
(SUV) and macro parameter determination (Loganref) methods
To investigate the capability of the macro parameter method to
distinguish small differences in tracer uptake between groups, the
DVR in non- vs. doxorubicin-treated FaDu-bearing mice was calcu-
lated by the Loganref method and comparedwith those determined by
the conventional SUV method (Fig. 4). The SUV analysis indicated a
trend toward an increase in [methyl-11C]-H6-AnxA5-ST-CH3 uptake
after doxorubicin treatment (d = 1.2), but the differences between
groups were only statistically signiﬁcant (i.e. p b 0.05) when the DVR
Fig. 2. (A) A maximum intensity projection and magniﬁcation in the trans-axial dimension showing the tumour and region of interest for a typical doxorubicin treated mouse.
Radioactivity concentrations (SUVs) over time after the i.v. injection of [11C]-H6-AnxA5-ST-CH3 in (B) arterial blood; (C) the reference muscle tissue divided by that in the arterial
blood; (D) the tumour tissue divided by that in the reference tissue. Data were reconstructed into different time frames in order to capture the concentration ﬂuctuations.
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more than twenty times compared to the SUV results.
3.4. Comparison of DVRs for [methyl-11C]-H6-AnxA5-ST-CH3 and
[methyl-11C]-H6-mTrx-GFP-ST-CH3
The mean regressions gave the mean DVRs, for the labeled AnxA5
and mTrx-GFP as 2.03 and 2.16, respectively (Fig. 3B). The difference
between the two is not statistically signiﬁcant (p = 0.3). There is a
slightly greater spread in the regression lines for labeled mTrx-GFP,
but the proﬁles were surprisingly quite similar for the targeting and
non-targeting proteins. This analysis allows an estimation of the EPR
effect on the retention of both tracers in the target tissue. Since the
DVR is ≈ 2.1, the tumour tissue has a nearly two-fold larger
concentration of radioactivity than that in the reference region.
Furthermore, DVRs for the AnxA5 and mTrx-GFP are on the same
level, which indicates that any speciﬁc binding at baseline for the [11C]
AnxA5-ST is not separable from the uptake due to the EPR effects.
Since 11C-labeled mTrx-GFP shows the non-speciﬁc uptake due to
EPR effects, we also may have amethod for observing whether there are
changes in these effects due to treatment. In Fig. 5 the differences
between 11C-labeled AnxA5 uptake in treated animals vs. 11C-labeled
mTrx-GFP in untreated animals are shown for both the SUVmethod andthe Loganrefmethod (d = 0.03vs. 1.7). Statistical signiﬁcance is achieved
when comparing the DVRs (p = 0.0159) but not when comparing SUVs
between the two groups (p = 0.6905), a forty-fold difference.
4. Discussion
In this study we have compared the use of conventional SUV
analyses to a more involved kinetic analysis for assessing the uptake
and retention of intermediate-sized AnxA5-based protein radiotracer
and its size-matched control in untreated and doxorubicin-treated
subcutaneous peripheral tumours in SCID mice. We found that the
statistical signiﬁcance of inter-group comparisons was much higher
(≥20-fold) using the macro parameter method compared to the SUV
analyses. Statistical gains of this magnitude could potentially have a
very large impact, particularly in studies inwhich differences between
groups or conditions are very small.
SUV measurements are made at a time interval after equilibrium
has been achieved. Here the interval usedwas at 30–35 minutes, since
the tracer uptake thereafter tended to decrease and noise at late times
increased. Quantiﬁcations performed at speciﬁc, short time intervals
can potentially be inﬂuenced by unknown or uncontrolled individual
physiological variations, and this may have contributed to the lower
statistical certainty achieved here in the inter-group SUV comparisons
Fig. 3. (A): Example showing the Logan plots for the baseline investigations with [11C]-
H6-AnxA5-ST-CH3 in which the Loganrefmethod is used. The plots are adjusted to have
the same intersection to simplify visualization. (B): DVRs calculated by Loganart and
Loganref. The shaded horizontal lines display the mean of the measurements.
Fig. 4. Point plot showing the comparisons of SUVs to DVRs calculated for non-treated
and doxorubicin-treated FaDu xenograft-bearing mice. Data points are shifted
horizontally so that all points are visible. Cohen's d measured between AnxA5treated
DVR vs. AnxA5base DVR is approximately 2.5.
Fig. 5. Uptake of [11C]-H6-AnxA5-ST-CH3 in doxorubicin treated animal models (DVR)
compared to baseline [11C]-H6-mTrx-GFP-ST-CH3 animals (SUV) instead of baseline
[11C]-H6-AnxA5-ST-CH3 in Fig. 4. Data points are shifted horizontally so that all points
are visible. Cohen's d measured between AnxA5 treated DVR vs. mTrx-GFP baseline
DVR is approximately 1.7.
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data over a larger time interval from the dynamic scan after the semi-
equilibrium was achieved. The goodness of the ﬁt of the regression to
the data included was conﬁrmed by the chi-squared value, thereby
providing an objective test of the individual inclusion criteria. This can
be particularly valuable for monitoring changes in radioactivity
distributions when multiple factors may be affecting them as during,
for example, therapeutic protocols.
In describing an ideal, isolated system, the inﬂuences of a given
parameter can be examined by varying a speciﬁc parameter while all
other parameters are kept constant. This is not possible whenworking
with less ideal systems, like the biological processes involved here, in
which several other parameters may and do vary at the same time.
The use of ratios, like the distribution volume ratios or binding
potentials of a target to a reference region obtained from the graphical
analyses, can instead be used to minimize bias that may occur due to
other contributing but uncontrolled inﬂuences.
In preclinical imaging in mice it is difﬁcult to accurately determine
concentrations in the blood since very little blood can be taken from
these small animals throughout the entire scan. When instead using
image-derived data from the heart to determine concentrations, there
are very few voxels available, and accurately quantifying the
concentrations can be difﬁcult [38]. Furthermore, artefacts due to
breathing and heart movement cannot be minimized in mice by
gating, since appropriate equipment is not available. Thus the uptake
curves will be less continuous and the distribution volumes less well
deﬁned, which probably contributed to the spread for the DVRs
determined by Loganart in Fig. 3.
A speciﬁc uptake at baseline of [methyl-11C]-H6-AnxA5-ST-CH3
could not be estimated since essentially the same mean DVR
was obtained for the non-binding, size-matched control,
[methyl-11C]-H6-mTrx-GFP-ST-CH3. In addition, these mean DVRs
are greater than one, which indicates appreciable EPR effects on the
tracer uptake, even though these effects have previously been said to
become signiﬁcant for macromolecules above molecular weights of
40 kDa [39]. Our study indicates that the degree to which these effects
contribute to the uptake of intermediate to high molecular weight
tracers needs to be examined when validating the radioligand
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done by using a control ligand that is as similar to the targeting
protein in size and other physicochemical properties as possible.
Comparing radiotracer uptakes in two different tumour models with
different target levels or in tumours in different mouse strains will not
per se account also for possible underlying EPR effects on the tracer
uptake, unless vascularity and other aspects of the tumour microen-
vironments are also shown to be essentially identical.
Binding potentials can also be obtained from the Logan graphical
analyses by subtracting one from the DVR (BPND = DVR-1). In
quantifying neuroreceptor ligands, it is recognized that the BP can
only be used as a descriptor as long as the reference tissue has
negligible target densities. When using these techniques to model
tracer behaviour in tumours, the differences in vascular properties of
the reference and tumour tissues must also be taken into account. We
therefore suggest that it may bemore appropriate to use DVR than the
BPND to describe the uptake of these larger protein ligands thatmay be
leaking into but clearing slowly from the tumour.
The physician's view of the operational difﬁculties and practical
problems associated with different strategies for collecting and
analysing PET data in the clinic has recently been vivaciously and
provocatively discussed by Galli et al. [40]. Admittedly, the use of
optimized static imaging protocols and analyses using SUVs has had a
tremendous impact on facilitating the clinical use of PET. However,
there is a danger that widespread acceptance and use of these
streamlined protocols can block needs to probe in more detail the
information that can be obtained with the molecular imaging probes
when the results are not giving a clear-cut “yes” or “no”. So what are
the implications, if any, of the results of this study for the way in
which AnxA5- or potentially other radiolabelled probe-based molec-
ular imaging is used to study induced cell death in tumours?
Firstly, it should be pointed out that this inter-group comparison
included only a few individuals in each group and that only one
tumour type and one type of therapy were being examined. It was far
beyond the scope of this study to include enough investigations to
generalize the ﬁndings to all tumour types and all types of therapy. On
the contrary, the goal was quite the opposite: to illustrate that, on an
individual level (as is the case in clinical imaging), the underlying
pathophysiology and the pharmacological effects of therapy will most
certainly be affecting the rates of probe uptake and deposition in and
elimination from tumour tissue in manners that are far more complex
than increases and decreases in tracer concentrations that solely
reﬂect changes in the speciﬁc binding of the tracer. Additionally,
moderate changes in tracer uptake from one scan to another in the
same individual may not be detected with statistical signiﬁcance by
so-called conventional methods of analysis. Considerable levels of
uptake of radiolabelled AnxA5 in untreated tumours have previously
been interpreted to indicate basal on-going apoptosis in the tissue
[41]. However, our studies demonstrate that AnxA5 uptake may be
strongly inﬂuenced by EPR effects. These effects are most certainly
different for different tumour types [42]. They can vary at different
stages of tumour progression and most deﬁnitely throughout
successful therapy. The EPR effects should be estimated instead of
predicted, at least until enough observations (in early clinical trials?)
have been made to be able to make predictions. Furthermore, many
anti-cancer treatments also have effects on blood ﬂow, and/or the
tumour vasculature and these effects may or may not coincide with
the induced cell death [43]. To be sure that changes in labelled probe
uptakes are due to changes in target expressions, effects on the
vasculature must also be accounted for during the cell death imaging.
Here we have used a size-matched control protein to, as closely as
possible, estimate the extent of the non-binding contributions on the
tracer uptake. It is not likely that this technique can be used in the
clinic, but is rather more appropriate for studies in preclinical trials
before translating the knowledge gained to improve clinical protocols.
Other strategies for measuring vascularity in tumours have beendiscussed [44]. These may also be easier to test ﬁrst in preclinical
studies like this one, since multiple tracers and multiple imaging
sessions can be logistically difﬁcult in a clinical setting. Using
relatively rapidly clearing radiotracers like those used here could
facilitate such studies so the different parameters would be measured
in as close to the same time interval as possible.
Secondly, as pointed out in the introduction, disappointment with
experiences of AnxA5-based imaging of induced cell death has led to
the examination of even larger imaging probes to obtain cumulative
measures of PS externalization over days and the use of other probes
targeting other molecular targets important in apoptosis. We suggest,
based on our results, that these studies also need to be closely coupled
to other measures of vascular contributions to the tracer uptake,
retention and elimination from the tumour tissue.
Thirdly, since bioengineering is affording more and more inter-
mediate-sized probes for targeting speciﬁc processes, it is important
to critically examine how the imaging data obtained with these
radiolabeled probes might be analyzed. We have shown that
performing dynamic scans and kinetic analyses can be essential for
revealing e.g. small differences in therapeutic effects. We also show
that it is important to identify other factors behind the radiotracer
localizations, particularly in tissue with compromised vasculature and
lymphatics, like the tumors studied here. Performing these kinds of
analyses in preclinical settings as a ﬁrst line of analysis can potentially
contribute to a better understanding of how similar techniques might
or might not be implemented clinically.5. Conclusions
Our ﬁndings indicate that use of Logan graphical analyses for
reversibly binding tracers can be utilized to describe the behaviour of
[methyl-11C]-H6-AnxA5-ST-CH3 in peripheral head and neck xeno-
grafts in mice and that muscle tissue can be used as the reference
tissue. Furthermore, evaluations of this intermediate-sized tracer in
peripheral tumour tissues need to take into account the non-speciﬁc
uptake due to EPR effects and also their changes during disease
progression or therapy. Since the level of speciﬁc binding of
radiolabelled AnxA5 uptake in the tumours is small, the more
complex macro parameter-based methods were required for ﬁnding
differences in inter-group comparisons. Here statistical signiﬁcance
was achieved when the DVRs but not when the SUVs were compared
(p b 0.008 and p N 0.05, respectively).Conﬂict of interest
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